Health Technology Assessment

63 Items

All Items

  • Heart failure and economic impact: an analysis in real clinical practice in Italy

    Melania Dovizio, Melania Leogrande, Luca Degli Esposti
    DOI: https://doi.org/10.33393/grhta.2024.3013
  • The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain

    Maria Merino, Paulina Maravilla-Herrera, Teresa Martín Lorenzo, Juan Antonio Arance, Julio Bobes, Montse Corrales, Fátima Guzmán, María Morales, Carlos Mur
    82-93
    DOI: https://doi.org/10.33393/grhta.2024.2697
  • The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example

    Mickaël Hiligsmann, Olivier Bruyère
    75-81
    DOI: https://doi.org/10.33393/grhta.2024.2682
  • Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

    Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio
    55-67
    DOI: https://doi.org/10.33393/grhta.2024.2658
  • Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

    Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio
    38-50
    DOI: https://doi.org/10.33393/grhta.2024.2728
  • Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis

    Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti
    31-37
    DOI: https://doi.org/10.33393/grhta.2024.2639
  • A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

    Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti
    1-16
    DOI: https://doi.org/10.33393/grhta.2024.2601
  • Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

    Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee
    62-69
    DOI: https://doi.org/10.33393/grhta.2023.2561
  • Good practices for the development of budget impact models at regional level

    Andrea Marcellusi, Angela Ragonese, Andrea Marinozzi, Alberto Bortolami, Sara Mucherino, Carolina Moreno, Amalia Antenori, Matteo Ferrario, Claudia Simonelli, Matteo Zanuzzi, Marco Cicoira, Ruggero Lasala, Francesco Russoniello, Francesco Attanasio, Caterina Donati, Chiara Roni, Fabrizio Gemmi, Francesco Saverio Mennini, Pierluigi Russo, Giovanna Scroccaro, PierLuigi Canonico
    53-61
    DOI: https://doi.org/10.33393/grhta.2023.2582
  • COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

    Beatrice Canali, Laura Candelora, Francesca Fiorentino, Tom Halmos, Paola La Malfa, Francesca Massara, Chiara Vassallo, Duccio Urbinati
    46-52
    DOI: https://doi.org/10.33393/grhta.2023.2560
  • Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

    Francesca Fiorentino, Paolo Di Rienzo
    29-39
    DOI: https://doi.org/10.33393/grhta.2023.2507
  • Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections

    Martina Paoletti, Andrea Marcellusi, Joe Yang, Francesco Saverio Mennini
    18-28
    DOI: https://doi.org/10.33393/grhta.2023.2488
  • Budget Impact analysis of a new system of care in Parkinson’s disease patients

    Chiara Bini, Francesco Saverio Mennini, Andrea Marcellusi, Martina Paoletti, Carlo Tomino
    91-98
    DOI: https://doi.org/10.33393/grhta.2022.2413
  • Disability weights for castration-resistant prostate cancer: an empirical investigation

    Ludovica Borsoi, Oriana Ciani, Rocco De Vivo, Giorgio Ivan Russo, Marcello Scarcia, Chiara De Fino, Patrizia Beccaglia, Irene Luccarini
    146-154
    DOI: https://doi.org/10.33393/grhta.2022.2431
  • Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

    Giuseppe Pompilio, Davide Integlia
    138-145
    DOI: https://doi.org/10.33393/grhta.2022.2474
  • Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

    Prof. Dr. Jaime Rodríguez Quintosa, Dr. Cintia Cristina Ago, Dr. Antoni Sicras Mainar, Dr. Renata Villoro, Dr. Inés Pérez-Román
    133-137
    DOI: https://doi.org/10.33393/grhta.2022.2439
  • Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

    Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria
    123-132
    DOI: https://doi.org/10.33393/grhta.2022.2470
  • Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

    Chiara Bini, Martina Paoletti, Andrea Marcellusi, Carlo Tomino, Francesco Saverio Mennini
    105-116
    DOI: https://doi.org/10.33393/grhta.2022.2412
  • Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

    Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo
    82-90
    DOI: https://doi.org/10.33393/grhta.2022.2449
  • The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

    Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi
    73-81
    DOI: https://doi.org/10.33393/grhta.2022.2415
  • Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

    Filippo Rumi, Michele Basile, Americo Cicchetti, Rosario Contiguglia, Antonella Pentassuglia, Alessandro Oliva, Gianenrico Senna, Marco Bonavia, Francesco Scarpelli, Marco Benvenuto
    58-67
    DOI: https://doi.org/10.33393/grhta.2022.2290
  • Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

    Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni
    45-57
    DOI: https://doi.org/10.33393/grhta.2022.2287
  • Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution

    Filippo Rumi, Francesca Orsini, Vincenzo Falabella, Pier Raffaele Spena, Americo Cicchetti
    36-44
    DOI: https://doi.org/10.33393/grhta.2022.2292
  • Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

    Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia
    22-29
    DOI: https://doi.org/10.33393/grhta.2022.2351
  • A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

    Néboa Zozaya, Teresa Caballero, Teresa González-Quevedo, Pedro Gamboa Setien, M. Ángeles González, Ramón Jódar, José Luis Poveda-Andrés, Encarna Guillén-Navarro, Agustín Rivero Cuadrado, Álvaro Hidalgo-Vega
    14-21
    DOI: https://doi.org/10.33393/grhta.2022.2333
1-25 of 63